Leung General, Kirpalani Anish, Szeto Stephen G, Deeb Maya, Foltz Warren, Simmons Craig A, Yuen Darren A
Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital.
Department of Medical Imaging, St. Michael's Hospital.
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):1019-1028. doi: 10.2215/CJN.07900716. Epub 2017 Mar 15.
A key contributor to the progression of nearly all forms of CKD is fibrosis, a largely irreversible process that drives further kidney injury. Despite its importance, clinicians currently have no means of noninvasively assessing renal scar, and thus have historically relied on percutaneous renal biopsy to assess fibrotic burden. Although helpful in the initial diagnostic assessment, renal biopsy remains an imperfect test for fibrosis measurement, limited not only by its invasiveness, but also, because of the small amounts of tissue analyzed, its susceptibility to sampling bias. These concerns have limited not only the prognostic utility of biopsy analysis and its ability to guide therapeutic decisions, but also the clinical translation of experimental antifibrotic agents. Recent advances in imaging technology have raised the exciting possibility of magnetic resonance imaging (MRI)-based renal scar analysis, by capitalizing on the differing physical features of fibrotic and nonfibrotic tissue. In this review, we describe two key fibrosis-induced pathologic changes (capillary loss and kidney stiffening) that can be imaged by MRI techniques, and the potential for these new MRI-based technologies to noninvasively image renal scar.
几乎所有形式的慢性肾脏病进展的一个关键因素是纤维化,这是一个基本上不可逆的过程,会导致进一步的肾脏损伤。尽管其很重要,但临床医生目前尚无无创评估肾瘢痕的方法,因此历来依靠经皮肾活检来评估纤维化负担。尽管肾活检在初始诊断评估中有所帮助,但对于纤维化测量而言,它仍然是一项不完善的检测方法,不仅受其侵入性的限制,而且由于所分析的组织量少,还容易受到抽样偏差的影响。这些问题不仅限制了活检分析的预后效用及其指导治疗决策的能力,还限制了实验性抗纤维化药物的临床转化。成像技术的最新进展带来了基于磁共振成像(MRI)进行肾瘢痕分析的令人兴奋的可能性,这是利用了纤维化组织和非纤维化组织不同的物理特征。在本综述中,我们描述了两种可通过MRI技术成像的关键纤维化诱导的病理变化(毛细血管丧失和肾脏硬化),以及这些基于MRI的新技术对肾瘢痕进行无创成像的潜力。